Drug Search Results
More Filters [+]

CpG-STAT3 siRNA CAS3/SS3

Alternative Names: CpG-STAT3 siRNA CAS3/SS3, CpG-STAT3 siRNA, CpG-STAT3siRNA
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TLR9 Inhibitor,STAT3 Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: City of Hope Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CpG-STAT3 siRNA CAS3/SS3

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Mantle-Cell Lymphoma|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2021-06965

P1

Withdrawn

Chronic Lymphoid Leukemia|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma

2024-01-04

Recent News Events